{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:52:07Z","timestamp":1790488327663,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/pas.0b013e318243555b","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T07:24:20Z","timestamp":1328599460000},"page":"629-639","source":"Crossref","is-referenced-by-count":102,"title":["Vascular Endothelial Growth Factor Receptor 2 as a Marker for Malignant Vascular Tumors and Mesothelioma"],"prefix":"10.1097","volume":"36","author":[{"given":"Markku","family":"Miettinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit-Sarlomo","family":"Rikala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Rys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Lasota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210131","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0304-3835(97)00280-2","article-title":"Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylaseplatelet-derived endothelial cell growth factor expression in human colorectal cancer.","volume":"119","author":"Amaya","year":"1997","journal-title":"Cancer Lett"},{"key":"R2-17-20210131","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1158\/0008-5472.CAN-09-2068","article-title":"KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.","volume":"69","author":"Antonescu","year":"2009","journal-title":"Cancer Res"},{"key":"R3-17-20210131","first-page":"1065","article-title":"Strong expression of kinase insert domain-containing receptor, a vascular permeability factorvascular endothelial growth factor receptor in AIDS-associated Kaposis sarcoma and cutaneous angiosarcoma.","volume":"148","author":"Brown","year":"1996","journal-title":"Am J Pathol"},{"key":"R4-17-20210131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1242\/jcs.113.1.59","article-title":"Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during enchondral bone formation.","volume":"113","author":"Carlevaro","year":"2000","journal-title":"J Cell Sci"},{"key":"R5-17-20210131","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0925-4773(99)00030-1","article-title":"Differential expression of KDRVEGFR-2 and CD34 during mesoderm development of the early human embryo.","volume":"83","author":"Cortes","year":"1999","journal-title":"Mech Dev"},{"key":"R6-17-20210131","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6602109","article-title":"Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.","volume":"91","author":"Dev","year":"2004","journal-title":"Brit J Cancer"},{"key":"R7-17-20210131","first-page":"97","article-title":"CD31: an immunospecific marker for endothelial differentiation in human neoplasms.","volume":"1","author":"De Young","year":"1993","journal-title":"Appl Immunohistochem"},{"key":"R8-17-20210131","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/PAS.0b013e318033c7c4","article-title":"Germ cell tumors with sarcomatous components: a clinicopathological and immunohistochemical study of 46 cases.","volume":"31","author":"Dominguez-Malagon","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R9-17-20210131","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1002\/cncr.25333","article-title":"Combination of low vascular endothelial growth factor A (VEGF-A)VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer.","volume":"116","author":"Donnem","year":"2010","journal-title":"Cancer"},{"key":"R10-17-20210131","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2005.09.018","article-title":"Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.","volume":"42","author":"Duff","year":"2006","journal-title":"Eur J Cancer"},{"key":"R11-17-20210131","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1530\/EJE-10-0849","article-title":"Vascular endothelial growth factor and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.","volume":"64","author":"Farkkila","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R12-17-20210131","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.humpath.2008.06.004","article-title":"High levels of vascular endothelial growth factor and its receptors (VEFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.","volume":"39","author":"Ghosh","year":"2008","journal-title":"Hum Pathol"},{"key":"R13-17-20210131","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07942.x","article-title":"Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).","volume":"148","author":"Gratzinger","year":"2009","journal-title":"Brit J Hematol"},{"key":"R14-17-20210131","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jcp.2010.085142","article-title":"Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma.","volume":"64","author":"Huang","year":"2011","journal-title":"J Clin Pathol"},{"key":"R15-17-20210131","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nm.1877","article-title":"Suppressed NFAT-dependent VEGF1 expression and constitutive VEGFR2 signaling in infantile hemangioma.","volume":"14","author":"Jinnin","year":"2008","journal-title":"Nat Med"},{"key":"R16-17-20210131","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/modpathol.3880543","article-title":"Monoclonal antibody D2-40 a new marker of lymphatic endothelium, reacts with Kaposis sarcoma and a subset of angiosarcomas.","volume":"15","author":"Kahn","year":"2002","journal-title":"Mod Pathol"},{"key":"R17-17-20210131","doi-asserted-by":"crossref","first-page":"652320","DOI":"10.1155\/2010\/652320","article-title":"Molecular and clinical aspects of targeting the VEGF pathway in tumors.","volume":"2010","author":"Korpanty","year":"2010","journal-title":"J Oncol"},{"key":"R18-17-20210131","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.humpath.2009.08.016","article-title":"Quantitative expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-R3 in melanoma tissue microarrays.","volume":"41","author":"Mehnert","year":"2010","journal-title":"Hum Pathol"},{"key":"R19-17-20210131","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00000478-200109000-00007","article-title":"CD31 expression in intratumoral macrophages: a potential diagnostic pitfall.","volume":"25","author":"McKenney","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R20-17-20210131","first-page":"82","article-title":"Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigensevaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrands factor.","volume":"7","author":"Miettinen","year":"1994","journal-title":"Mod Pathol"},{"key":"R21-17-20210131","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/PAS.0b013e318206b67b","article-title":"ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.","volume":"35","author":"Miettinen","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R22-17-20210131","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1097\/PAS.0b013e318229a401","article-title":"Claudin 5 as immunohistochemical marker for angiosarcoma and hemangioendotheliomas.","volume":"35","author":"Miettinen","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R24-17-20210131","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/00005537-200110000-00031","article-title":"Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck.","volume":"111","author":"Neuchrist","year":"2001","journal-title":"Laryngoscope"},{"key":"R25-17-20210131","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2009.02.022","article-title":"Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.","volume":"45","author":"Nutt","year":"2009","journal-title":"Eur J Cancer"},{"key":"R26-17-20210131","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CCO.0b013e32833aaad4","article-title":"Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytomasolitary fibrous tumor.","volume":"22","author":"Park","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"R27-17-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00008390-200502000-00007","article-title":"VEGF and VEGFR-2 immunohistochemistry in human melanocytic nevi and cutaneous melanomas.","volume":"15","author":"Pisacane","year":"2005","journal-title":"Melanoma Res"},{"key":"R28-17-20210131","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/B:BREA.0000004357.92232.cb","article-title":"Tumor specific VEGF-A and VEGFR2KDR protein are co-expressed in breast cancer.","volume":"82","author":"Ryden","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"R29-17-20210131","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2334\/josnusd.51.551","article-title":"VEGFR2 expression and relationship between tumor neovascularization and histologic characteristics in oral squamous cell carcinoma.","volume":"4","author":"Sato","year":"2009","journal-title":"J Oral Sci"},{"key":"R30-17-20210131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.lungcan.2006.02.009","article-title":"Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage 1 non-small-cell lung cancer.","volume":"53","author":"Seto","year":"2006","journal-title":"Lung Cancer"},{"key":"R31-17-20210131","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00384-009-0843-7","article-title":"K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFR in colorectal cancer.","volume":"25","author":"Schimanski","year":"2010","journal-title":"Int J Colorect Dis"},{"key":"R32-17-20210131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/10623320600697955","article-title":"Vascular endothelial growth factor (VEGF)-receptor 2: its biological functions, major signaling pathway, and specific ligand VEGF-E.","volume":"13","author":"Shibuya","year":"2006","journal-title":"Endothelium"},{"key":"R33-17-20210131","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-09-2797","article-title":"Vascular endothelial growth factor receptors VEGFR2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R34-17-20210131","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.1997.15.2.826","article-title":"Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma.","volume":"15","author":"Tanigawa","year":"1997","journal-title":"J Clin Oncol"},{"key":"R35-17-20210131","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/gcc.10028","article-title":"Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.","volume":"33","author":"Walter","year":"2002","journal-title":"Genes Chromosom Cancer"},{"key":"R36-17-20210131","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","article-title":"Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.","volume":"175","author":"Xia","year":"2006","journal-title":"J Urol"},{"key":"R37-17-20210131","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozanitib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0b013e318243555b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:38:36Z","timestamp":1786048716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000478-201204000-00017"}},"subtitle":["An Immunohistochemical Study of 262 Vascular Endothelial and 1640 Nonvascular Tumors"],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0b013e318243555b","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}